Harmony Biosciences Undervalued by 80.1% According to DCF Analysis

Harmony Biosciences Holdings is priced undervalued by 80.1% based on its Discounted Cash Flow (DCF) analysis, with a projected intrinsic value of $189.50 per share. The share price closed at $37.68, with a 4.9% gain over the last 7 days and a 1.9% decline over the past year. The stock has seen mixed shorter term and longer term returns, with ongoing coverage of its role in the pharmaceuticals and biotech space and discussion of its key products and pipeline.